Buy Rating for ODDITY Tech Ltd. Amid Strong Growth and Strategic ExpansionWe reiterate our Buy rating, $72 PT following strong Q3 results, with growth remaining strong despite the challenging macro. Growth continues to be driven by domestic markets, while internationally, efforts are early, but revenue is scaling at a 40% clip YTD. In our view, further penetration of the existing international geos, as well as efforts in newly announced target markets, provide ample growth levers for the company to maintain 20%+ growth. Adding to the quiver is the recent launch of Brand 3, now known as METHODIQ, which greatly expands the TAM in dermatology; while scaling will take time, management is already bullish the brand can scale faster than prior launches. While ODD is still orienting investors towards a 20/20 growth & EBITDA margin profile in FY26, we see multiple levers to drive topline upside, keeping us Buy rated.